Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical STIL::TAL1 fusion events

by Mahsa Khanlari, Wei Wang, Yen-Chun Liu, Lu Wang, Jeffrey E. Rubnitz, Stephanie Dixon, Brent A. Orr, Obianuju M. Anelo, Zhongshan Cheng, Vidya Balagopal, and Jeffery M. Klco

Received: May 23, 2023.
Accepted: September 18, 2023.


Publisher’s Disclaimer.
E-publishing ahead of print is increasingly important for the rapid dissemination of science. Haematologica is, therefore, E-publishing PDF files of an early version of manuscripts that have completed a regular peer review and have been accepted for publication. E-publishing of this PDF file has been approved by the authors. After having E-published Ahead of Print, manuscripts will then undergo technical and English editing, typesetting, proof correction and be presented for the authors’ final approval; the final version of the manuscript will then appear in a regular issue of the journal. All legal disclaimers that apply to the journal also pertain to this production process.
Concurrent peripheral T-cell lymphoma and T-cell lymphoblastic leukemia/lymphoma with identical \textit{STIL::TAL1} fusion events

Mahsa Khanlari\textsuperscript{1}, Wei Wang\textsuperscript{2}, Yen-Chun Liu\textsuperscript{1}, Lu Wang\textsuperscript{1}, Jeffrey E. Rubnitz\textsuperscript{3}, Stephanie Dixon\textsuperscript{3}, Brent A. Orr\textsuperscript{1}, Obianuju M. Anelo\textsuperscript{4}, Zhongshan Cheng\textsuperscript{5}, Vidya Balagopal\textsuperscript{1}, Jeffery M. Klco\textsuperscript{1}

\textsuperscript{1}Department of Pathology, St. Jude Children's Research Hospital, Memphis, TN, USA
\textsuperscript{2}Department of Hematopathology, MD Anderson Cancer Center, Houston, TX, USA
\textsuperscript{3}Department of Oncology, St. Jude Children's Research Hospital, Memphis, TN, USA
\textsuperscript{4}Department of Pathology, University of Tennessee Health Science Center, TN, USA
\textsuperscript{5}Center for Applied Bioinformatics, St. Jude Children's Research Hospital, Memphis, TN, USA

**Running heads:** Concurrent PTCL and T-LBLL with \textit{STIL::TAL1} fusion

**Corresponding author:**
Mahsa Khanlari, MD
Assistant Professor
St. Jude Children's Research Hospital
262 Danny Thomas Place
Department of Pathology, Mail Stop 250
Memphis, TN 38105
Email: mahsa.khanlari@stjude.org
Phone: 901-595-0394

Word count: main text (1489), 3 figures

Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Disclosure: The authors declare no conflicts of interest.

Data availability statement: The data that support the findings of this study are available from the corresponding author upon reasonable request.

Contributions: All authors wrote and approved the final version of the manuscript. ZC and VB performed molecular research and data analysis.
The World Health Organization and the International Lymphoma Study Group have broadly placed neoplasms with T-cell lineage into lymphomas/leukemias with a precursor T-cell phenotype (e.g., T-lymphoblastic leukemia/lymphoma (T-LBLL)) and those with a mature T-cell phenotype (e.g., Peripheral T-cell Lymphoma (PTCL)).\(^1\) The accurate classification of lymphoid neoplasms is vital as it determines the subsequent therapy. Historically, in the context of normal T-cell (thymocyte) development, T-LBLL differentiation stages have been identified based on the expression of cluster differentiation (CD) proteins as early, pro-T, pre-T, cortical T, and mature T.\(^2\) Genomic analysis has enabled identifying genetic drivers and signaling pathway alterations associated with different maturational stages of T-cells in T-LBLL.\(^3,4\)

Genetic alterations in T-LBLL are mainly composed of master regulators of T-cell fate and differentiation with genes affected in the encoding of transcription factors (e.g., \(TAL1/2, LMO1/2, TLX, NKX2-1, BCL11B, HOXA\)), along with cooperating abnormalities that influence cell cycle, epigenetic and signal transduction.\(^5\) Ectopic expression of \(TAL1/SCL\) (transcription factor located on chromosome 1p33) resulting from \(STIL::TAL1\) fusion, deletion, or upstream intergenic non-coding mutations is identified in 11%–27% of T-LBLL cases.\(^6,7\) \(STIL::TAL1+\) pediatric T-LBLL cases are heterogeneous in terms of their stages of T-cell development. Although not exclusive, certain types of cooperating abnormalities, such as \(PTEN\) and \(PIK3R\) mutations, are more frequently found in \(TAL1\)-positive cases and correlate with late cortical and mature T-cell immunophenotypes.\(^3\)

PTCL other than anaplastic large-cell lymphoma is rare in pediatric patients and includes PTCL, not otherwise specified (NOS), and mature T/NK-cell neoplasms, characterized by atypical cells with properties of mature T/NK cells.\(^1,8,9\) PTCL-NOS can be further sub-classified into those that highly express one of two transcription factors (GATA-3 or T-bet/TBX21) that regulate normal T-cell differentiation.\(^10\) A heterogeneous genetic landscape of cooperating mutations further characterizes these subtypes in PTCL-NOS.\(^10,11\)
Relapses often characterize the natural history of malignant hematopoietic diseases after therapy. The neoplastic clone(s) in relapse are often related to the initial clone(s) but might exhibit additional aberrations, clonal selection, transformation, or phenotypic changes. However, the co-existence of two morphologically and phenotypically distinct but genetically related neoplasms of the T-cell lineage at initial presentation has only been rarely reported previously in T-cell neoplasms. Here, we report on a child presenting with cutaneous T-cell infiltrate diagnosed as PTCL-NOS with concurrent T-LBLL diagnosed in the bone marrow (BM) before the start of therapy. The two tumors shared the same genetic alterations in addition to those uniquely present in each.

The patient was a 10-year-old girl who presented with a single erythematous skin swelling in the mid-back that progressed to an ulcerated mass (6x3 cm) in 3 months. No fever, night sweats, or weight loss were reported. Microscopic evaluation of the lesion showed an atypical infiltrate composed of monotonous cells with a rim of clear cytoplasm, densely clumped chromatin, and small nucleoli. By immunohistochemical stains, the atypical infiltrate was positive for CD2, CD3, CD4 (small subset), CD5, CD8, TIA-1, granzyme B, T-cell receptor (TCR)-beta, TBX21, GATA3, and negative for CD1a, CD7, CD10, CD20, Pax-5, CD30, CD34, CD56, CD79a, ALK-1, TCR-delta, TdT, and EBER (In situ hybridization) (Figure 1A). The Ki-67 proliferation index was 70%. The overall findings are consistent with PTCL-NOS with CD8+ cytotoxic phenotype. With the expression of TBX21, we further subclassified the case as T-bet PTCL subtype.

The subsequent positron emission tomography–computed tomography (PET-CT) study for staging showed widespread abnormal uptake in numerous lymph nodes, liver, kidneys, left femur along with a pleural effusion. Complete blood count showed a white cell count of $11.23 \times 10^9$/L, hemoglobin of 95 g/L, and platelet count of $280 \times 10^9$/L. The patient also had elevated serum LDH level (1959 U/L, reference range 165–310 U/L). BM examination revealed a hypercellular marrow (>95%) with numerous blasts. Blasts were medium in size with a scant amount of basophilic cytoplasm (some vacuolated), irregular nuclear contours, and inconspicuous nucleoli. By immunohistochemical and multicolor flow cytometry immunophenotyping, blasts were positive for CD1a, CD2, cytoplasmic CD3, CD4 (partial), CD7, CD8
(partial), and TdT and negative for surface CD3, CD79a, TCR-beta, and TCR-delta (Figure 1B, C). The conventional karyotyping analysis showed 47,XX,+17[8]/46,XX[12]. These findings are diagnostic for T-LBLL. The patient was treated with standard therapy for acute lymphoblastic leukemia. She became minimal residual disease (MRD)-negative by day 15 of therapy and remains in complete remission. The site of excised skin mass healed without complication, and no other skin lesion was detected.

Whole genome sequencing (WGS), whole exome sequencing (WES), and RNA-sequencing (RNA-Seq) were performed on the BM sample along with WES and RNA-Seq from formalin-fixed, paraffin-embedded tissue of the skin lesion. The BM and skin tumor specimens shared an identical STIL::TAL1 fusion (Figure 2A). Both samples had additional 'private' discrete cooperating mutations. The BM sample included mutations in FBXW7, PIK3CA, KRAS, PTEN, SMARCA4, NOTCH1, BCL11B, and deletion of NOTCH1, CDKN2A, and CDKN2B. A different FBXW7 mutation was detected in the skin sample along with a structural variant leading to a PDGFRA::LEF1 fusion. Targeted resequencing validated these findings and further highlighted the different FBXW7 mutations in the skin and BM tumors (Figure 3B). By PCR, clonal TCR gamma rearrangement peaks were identified and identical in tumor samples from the skin and BM, confirming their shared origin (Figure 3A).

Despite the significant difference in morphology, immunophenotype, and secondary mutations, the tumors from the BM sample (T-LBLL phenotype) and the skin sample (PTCL, mature T-cell phenotype) had common origins, as confirmed by the shared STIL::TAL1 fusion and supported by the identical PCR amplification peaks in TCR clonality analysis. Our genomic characterization suggests the clonal relationship likely reflects a common cell of origin with divergent clonal evolution rather than parallel clonal evolution of diverse and unrelated precursors. In the absence of a therapeutic effect, it may be hypothesized that the extrinsic factors, such as cellular environment, immune pressure, cytokine stimulation, etc., differentially impact the tumor cells at distinct sites and promote the evolution of the same clone down different lineage trajectories yielding diverse morphology and immunophenotype.

STIL::TAL1+ T-LBLLs have previously been shown to be driven by reiterative mutations of the same driver
genes and resultant parallel clonal evolution in which STIL::TAL1 fusion and CDKN2A loss are both early or truncal events while NOTCH1 and PIK3/AKT/PTEN mutations are secondary and subclonal events in the evolutionary pathway. The heterogeneous nature of STIL::TAL1+ T-LBLL cases with respect to their immunophenotype has also been previously demonstrated in which TAL1+ cases clustered into two subgroups: double positive (DP, CD4+ CD8+) T-LBLL cases with a higher surface CD3 expression and a second smaller group with less surface CD3 expression. Subsequent evaluation of these clusters found the first cluster of T-LBLL cases containing mature T-LBLL (DP, CD4+ CD8+) was enriched with deletions in LEF1, CASP8AP2, CDKN2A/B in addition to STIL::TAL1 gene fusion.

Extranodal presentation of this case further adds to the challenges in proper classification and diagnosis. While the incidence rate of all cutaneous T-cell lymphomas in the pediatric age group is low, most cases are within the category of mature T-cell neoplasms. In contrast, skin is infrequently involved by precursor lymphoblastic lymphomas and rarely in T-LBLL. There is also limited data on the molecular analysis of T-LBLL cases presenting with the skin lesion.

In this case, a novel PDGFRA::LEF1 fusion was detected by sequencing analysis in skin sample with a breakpoint within exon 13 of the PDGFRA gene and exon 3 of the LEF1 gene resulting from an intrachromosomal inversion on chromosome 4q, which caused an out-of-frame fusion (Figure 2B). While the significance of this structural variant cannot be determined, there was insufficient evidence to support an activating PDGFRA rearrangement. This alteration spanning over multiple LEF1 exons can potentially disrupt the LEF1 gene, leading to its loss of function. It is hypothesized that LEF1 can play multiple roles in T-cell leukemia as a cooperative tumor suppressor or oncogene. As a tumor suppressor (and possible transcriptional repressor of MYC), it is inactivated in approximately 11% of pediatric T-LBLLs. Interestingly, LEF1-inactivated T-LBLLs have been characterized by the lack of CD34 expression and arrest at a transition from CD8+ immature single positive stage to double positive stage. This finding may potentially explain the mature immunophenotype of T-cell infiltrate in the skin sample compared to the BM tumor.
In summary, this case expands the complexity of cases with \textit{STIL::TAL1} fusion to T cell neoplasms with mature phenotypes. A potential collaborating effect exists between the \textit{STIL::TAL1} fusion and gene abnormalities that shape the T-cell neoplasm's morphologic and immunophenotypic features. Classification and diagnosis of T-cell neoplasms based on morphology and immunophenotypic features alone may be inadequate to fully characterize the ill-defined boundary between mature T-LBLL and PTCL. Primary cutaneous T-cell lymphoma/leukemia is rare in pediatric patients, and due to the rarity of these cases, \textit{TAL-1/2} is not routinely tested. However, our study draws attention to this rare event, and comprehensive cytogenetic and molecular studies would be indicated in extranodal and cutaneous T-cell infiltrates in pediatric patients.
References:

Figure legends:

**Figure 1. Skin and BM tumor morphology and immunophenotype**

(A) Skin biopsy shows infiltration of neoplastic lymphoid cells with a rim of clear cytoplasm, densely clumped chromatin, and small nucleoli (hematoxylin and eosin, x1000; inset, x40). Immunohistochemical analysis shows the neoplastic lymphoid cells are positive for CD3 (x100), and CD8 (x100) and are negative for CD7 (x100), and TdT (x200).

(B) BM core biopsy shows a hypercellular marrow diffusely involved by blasts (hematoxylin and eosin stain, x1000). Aspirate shows medium-sized neoplastic cells with blastoid chromatin and occasional small nucleoli (Wright-Giemsa, inset, x1000; oil). By immunohistochemical analysis, the blasts are positive for CD3 (x200), CD7 (x400), CD8 (x400), and TdT (x200).

(C) BM flow cytometry immunophenotyping analysis demonstrates a distinct population of aberrant T cells (red population) expressing CD45 (moderate expression), CD1a (moderate to bright), CD5 (bright with similar intensity to mature lymphocytes highlighted in blue population), and CD7 (bright). CD4 and CD8 are partially expressed.

Abbreviation; BM: Bone marrow

**Figure 2. Skin and BM tumor clonal history and novel fusion detected in the skin tumor**

(A) The same TAL1::STIL fusion transcripts are identified in both skin and BM samples. These fusion genes are further confirmed using whole genome sequencing data. For demonstration purposes, only fusion genes detected by RNA-seq data are presented in the figure. Fusion breakpoints are labeled according to the hg38 reference.

(B) RNA-seq analysis of skin and BM samples demonstrate a novel PDGFRA::LEF1 fusion, identified only in the skin sample, between PDGFRA (exon 13) and LEF1 (exon 3) on chromosome 4. The predicted fusion protein consists of the Ig-like domain of PDGFRA, followed by the intact transmembrane domain and TK domain of PDGFRA. Because the LEF1 gene is on the minus strand of chromosome 4, the creation of this fusion appears to have involved an intrachromosomal inversion. RNA read coverage is shown across the genes involved in the fusion.

Abbreviation; BM: Bone marrow; TK: Tyrosine kinase; RNA-seq: RNA sequencing

**Figure 3. Skin and BM tumor clonal history by TCR gamma gene rearrangement studies by PCR and proposed model of the evolutionary pathway**

(A) T-cell receptor (TCR) gamma gene rearrangement studies by PCR, performed on the skin and BM tumor samples, reveal a monoclonal rearrangement with identical PCR amplification peaks.

(B) Evolutionary pathway from a common progenitor with a common clone containing STIL::TAL1 event is demonstrated. The molecular alterations in different samples (skin and BM) are highlighted according to the different cellular machineries. The allele frequency of altered genes is represented in parenthesis.

The common molecular alteration in skin and BM, STIL::TAL1 del(1)(p33), appears in bold text.

Abbreviation; BM: Bone marrow; PCR: Polymerase chain reaction
A: Skin

[Graph showing data with peaks and size: 224,225]

A: BM

[Graph showing data with peaks and size: 224,225]

B

**STIL::TAL1 del(1)(p33)**

**LEF1::PDGFR** t(4)(q12;q25)

**FBXW7** R465H (48)

Skin

---

**STIL::TAL1 del(1)(p33)**

**NOTCH1**

**BCL11B** T450M (8)

**PTEN** R234fs (13)

**PTEN** K237* (12)

**PIK3CA** H1047R (10)

**KRAS** G12C (4)

**SMARCA4** P270fs (4)

---

**CDKN2A** del(9)(p21.3)

**CDKN2B** del(9)(p21.3)

**FBXW7** R479Q (9)

**FBXW7** R505H (2)

**NOTCH1** M1580>SL (6)

**NOTCH1** K2174fs (5)

**NOTCH1** del(9)(q34.3)